Correlation between BRCA1 expression and clinicopathological ...
Recommend Documents
expression. J Clin Invest 117: 3369-3382, 2007. 23. Kopan R and Ilagan MX: The canonical Notch signaling pathway: Unfolding the activation mechanism.
Supporting Table S3. Correlation between clinicopathological features and BIGH3 expression in tissue sections from 31 pancreatic cancer patients.
of ovarian cancers from the Gilda Radner familial ovarian cancer registry. Int J Gynecol Pathol, 23, 29-34. Wysham WZ, Mhawech-Fauceglia P, Li H, et al (2012).
By applying resampling techniques to simulated and real biological data sets, we have studied a ..... This setting is an analogue of the jackknife resampling used.
Clinicopathological Features of Oral Squamous Cell Carcinoma. Department of Clinical .... gingival. All cases of lip squamous cell carcinoma developed in men.
Jan 7, 2014 - Zhao L, Wang DL, Liu Y, Chen S and Sun FL: Histone acetyl- transferase hMOF promotes S phase entry and tumorigenesis in lung cancer.
Feb 12, 2019 - L2 expression was strongly consistent with PD-L1 expression, ... was deleted every time to judge its impact on the results. Frontiers in Oncology ..... m u ltiv a ria te. ;. U n i, u n iv a ria te . Frontiers in Oncology | www.frontier
Apr 22, 1991 - ... PETER REISSMANN*, CARLOS CORDON-CARDOt, MICHAEL ..... .f,/. Its. I. Is. FIG. 4. Immunohistochemical analysis of the expression of the.
Aug 25, 2014 - patients with cancer may develop skin metastases, while metastasis may .... [3] R. A. Schwartz, Skin Cancer: Recognition and Management,.
Feb 10, 2009 - type IV diffuse infiltrative (linitis plastica). In our cases, we identified: five type I carcinomas. (8.9%), 20 type II carcinomas (35.7%), 22 type III.
and CD8 in oral lichen planus ... Abstract. Objectives Oral lichen planus (OLP) is a chronic, inflamma- .... embedded in paraffin for histopathological examination,.
ment with buprenorphine/naloxone combination, buprenorphine and naltrex- one among patients diagnosed with opioid dependence; and to explore for.
and diffuse type cancer (poorly differentiated and signet ring cell types, p=0.001), as compared to gastric cancers in the. 585 patients older than age 31.
Jul 3, 2016 - Cancer cells use the indoleamine 2,3-dioxygenase 1 (IDO1) pathway to suppress the ... The expressions of IDO1, tryptophan 2,3-dioxygenase.
Correlation between BRCA1 expression and clinicopathological ...
Background. Previously identified as a breast and ovarian cancer susceptibility gene, BRCA1 has gained major scientific interest as a potential prognostic ...
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013 Sep; 157(3):227-232.
Correlation between BRCA1 expression and clinicopathological factors including brain metastases in patients with non-small-cell lung cancer Mariam Gachechiladzea, Ivo Uberalla,b, Vitezslav Kolekc, Jiri Kleind, Veronika Krejcia,b, Jitka Stastnaa, Lenka Radovae, Eddie Fridmanf, Josef Skardaa,b Background. Previously identified as a breast and ovarian cancer susceptibility gene, BRCA1 has gained major scientific interest as a potential prognostic and/or predictive marker for various tumors, including non-small-cell lung cancer (NSCLC), the leading cause of cancer related mortality worldwide. BRCA1 plays a central role in DNA damage response (DDR. It undergoes phosphorylation by various DDR kinases at different serine residues, of which ser1524 is known to be specifically phosphorylated by ATM in response to genotoxic stress. Methods. We performed BRCA1 immunohistochemistry on several tissue microarrays (TMAs) of 113 early (I, II stage) and advanced (III, IV stage) NSCLCs, using MS110 antibody against the BRCA1 N-terminal and S1524 antibody against the phosphorylated form of BRCA1 protein at ser1524 (Abcam). Patients with III and IV stage disease were treated by adjuvant cisplatin-based chemotherapy. Staining results were correlated with overall survival (OS), disease free survival (DFS) and with the occurrence of brain metastases. Results. BRCA1 S1524 nuclear positivity was significantly correlated with longer OS and DFS in stage I and II patients (P
